Minjee Lee1, Ramzi G Salloum2. 1. Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA. minjee@email.sc.edu. 2. Department of Health Outcomes and Policy, College of Medicine, University of Florida, Gainesville, FL, USA.
Abstract
PURPOSE: Cancer survivors are delaying or avoiding necessary care due to costs, and medication non-adherence is an important aspect of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by race and ethnicity and examines factors associated with CRN among cancer survivors. METHODS: Using the 2006-2013 National Health Interview Survey, we examine self-reported CRN among cancer survivors compared with cancer-free controls. Descriptive statistics and multiple logistic regression models were used to identify factors associated with CRN among cancer survivors. RESULTS: In a nationally representative sample of 472,542 adults, 10,998 participants reported a history of cancer and 461,544 did not. Among 10,998 cancer survivors, 1397 (12.70 %) reported CRN. Among older cancer survivors, African-Americans were 2.64 times more likely (95 % confidence interval (CI), 1.73 to 4.01) and Hispanics 2.07 times more likely (95 % CI, 1.32 to 3.24) than whites to report CRN. Among younger cancer survivors, Hispanics were 1.61 times more likely (95 % CI, 1.23 to 2.10) than whites to report CRN. CONCLUSIONS: Significant racial and ethnic disparities in CRN were evident among cancer survivors. Older African-American and Hispanic overall survivors were more likely to report CRN in the past year compared with non-Hispanic whites. IMPLICATIONS FOR CANCER SURVIVORS: Given increasing prescription drug expenditure, it is important to closely monitor CRN in high-risk subgroups. Racial and ethnic minority groups at high risk for CRN should be counseled on the importance of medication adherence and offered support services to promote medication adherence. Further studies are warranted to establish effective policies and interventions in vulnerable populations.
PURPOSE:Cancer survivors are delaying or avoiding necessary care due to costs, and medication non-adherence is an important aspect of deferred treatment. This study estimates the prevalence of cost-related medication non-adherence (CRN) by race and ethnicity and examines factors associated with CRN among cancer survivors. METHODS: Using the 2006-2013 National Health Interview Survey, we examine self-reported CRN among cancer survivors compared with cancer-free controls. Descriptive statistics and multiple logistic regression models were used to identify factors associated with CRN among cancer survivors. RESULTS: In a nationally representative sample of 472,542 adults, 10,998 participants reported a history of cancer and 461,544 did not. Among 10,998 cancer survivors, 1397 (12.70 %) reported CRN. Among older cancer survivors, African-Americans were 2.64 times more likely (95 % confidence interval (CI), 1.73 to 4.01) and Hispanics 2.07 times more likely (95 % CI, 1.32 to 3.24) than whites to report CRN. Among younger cancer survivors, Hispanics were 1.61 times more likely (95 % CI, 1.23 to 2.10) than whites to report CRN. CONCLUSIONS: Significant racial and ethnic disparities in CRN were evident among cancer survivors. Older African-American and Hispanic overall survivors were more likely to report CRN in the past year compared with non-Hispanic whites. IMPLICATIONS FOR CANCER SURVIVORS: Given increasing prescription drug expenditure, it is important to closely monitor CRN in high-risk subgroups. Racial and ethnic minority groups at high risk for CRN should be counseled on the importance of medication adherence and offered support services to promote medication adherence. Further studies are warranted to establish effective policies and interventions in vulnerable populations.
Entities:
Keywords:
Adherence; Cancer survivorship; Cost; Racial disparities
Authors: Kenneth M Langa; A Mark Fendrick; Michael E Chernew; Mohammed U Kabeto; Kerry L Paisley; James A Hayman Journal: Value Health Date: 2004 Mar-Apr Impact factor: 5.725
Authors: Maria Pisu; Andres Azuero; Karen Meneses; Jeffrey Burkhardt; Patrick McNees Journal: Breast Cancer Res Treat Date: 2010-10-26 Impact factor: 4.872
Authors: Deborah A Levine; Lewis B Morgenstern; Kenneth M Langa; John D Piette; Mary A M Rogers; Sudeep J Karve Journal: Ann Neurol Date: 2013-02-22 Impact factor: 10.422
Authors: Dong Wook Shin; Jong Hyock Park; Jae Hyun Park; Eun Cheol Park; So Young Kim; Sung Gyeong Kim; Jin Young Choi Journal: Support Care Cancer Date: 2010-01-15 Impact factor: 3.603
Authors: Jean A McDougall; Matthew P Banegas; Charles L Wiggins; Vi K Chiu; Ashwani Rajput; Anita Y Kinney Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-28 Impact factor: 4.254
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J A Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Date: 2021-09-28 Impact factor: 2.984
Authors: Nancy L Keating; Gabriel A Brooks; Mary Beth Landrum; Pang-Hsiang Liu; Robert Wolf; Lauren E Riedel; Nirav S Kapadia; Shalini Jhatakia; Amanda Tripp; Carol Simon; Van Doren Hsu; Colleen M Kummet; Andrea Hassol Journal: J Natl Cancer Inst Date: 2022-06-13 Impact factor: 11.816
Authors: Grace L Smith; Maria A Lopez-Olivo; Pragati G Advani; Matthew S Ning; Yimin Geng; Sharon H Giordano; Robert J Volk Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian Journal: Cancer Date: 2020-09-14 Impact factor: 6.860
Authors: Amy M Berkman; Clark R Andersen; Vidya Puthenpura; J Andrew Livingston; Sairah Ahmed; Branko Cuglievan; Michelle A T Hildebrandt; Michael E Roth Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-07-08 Impact factor: 4.254